TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to ...
In connection with the closing of the transaction contemplated by the Merger Agreement, a Fundamental Change occurred under the Indenture on February 5, 2025, which is the effective date of such ...
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it ...
Avid Bioservices plans to use the net proceeds to repurchase a portion of its 1.250% Exchangeable Senior Notes due 2026 and to repay any remaining 2026 Notes. This move follows an acceleration notice ...
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the ...
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate ...
Avid Bioservices, Inc. (CDMO) Investigation: Avid shares fell on Mar. 12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results